You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Antiviral Drugs for Lassa Fever Virus

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Hemorrhagic fever viruses are of serious worldwide health concern as well as potential biological weapons. Lassa fever virus in particular annually infects several hundred thousand individuals in West Africa, and the export of this pathogen outside of this region, either intentionally or unintentionally, presents a serious risk to the developed countries of the ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  2. Small Molecule Inhibitors of Smallpox Virus Replication

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Concern over the use of variola virus as a biological weapon has prompted interest in development of small molecule therapeutics for smallpox. Variola virus is highly transmissible and causes severe disease with high mortality rates. Currently, there is no FDA-approved drug for prevention or treatment of smallpox. The overall goal of this smallpox antiviral pro ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  3. Clinical Development a Therapeutic Agent for COPD

    SBC: BIOMARCK PHARMACEUTICALS, LTD            Topic: N/A

    Hypersecretion of mucus into the respiratory airways is a major contributing factor in several lung diseases, including chronic pulmonary disease (COPD), asthma, cystic fibrosis, and bronchiectasis. Despite the obvious medical importance, there presently are no effective therapies to control excess mucus secretion in these diseases, and very few potential therapeutic targets. We discovered that a ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  4. Preclinical development of novel small molecule malaria drugs that overcome drug

    SBC: DESIGNMEDIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The worldwide health problem created by malaria has been made more difficult by the spread of drug resistant parasites We have developed an orally available and inexpensive class of novel drugs that act against both chloroquine resistant and chloroquine sensitive malaria This project carries on preclinical development of a drug candidate that has been select ...

    STTR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  5. A human cytomegalovirus-based immunotherapy for HIV-1

    SBC: TOMEGAVAX, INC.            Topic: NIAID

    DESCRIPTION The ultimate goal of this project is to develop an immunotherapy for human immunodeficiency virus HIV based on a spread deficient cytomegalovirus CMV derived vaccine expressing andquot tailoredandquot antigens designed for maximal coverage of clade B epitopes In non human primate models rhesus CMV vectored vaccines demonstrated unprecedented protection against highly virulent ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Therapeutic Thrombin Analogs

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Project Summary/Abstract Treatment of acute ischemic stroke (AIS) with the thrombolytic/antithrombotic agent tissue plasminogen activator (tPA, Activase(R)) is limited due to the potential for severe hemorrhagic side effects. The first symptoms of acute ischemia to tPA treatment ( time to needle ) can span hours, even in developed urban areas, since an establis ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Therapeutic Thrombin Analogs

    SBC: ARONORA INC            Topic: NHLBI

    DESCRIPTION provided by applicant Project Summary Abstract Treatment of acute ischemic stroke AIS with the thrombolytic antithrombotic agent tissue plasminogen activator tPA Activase is limited due to the potential for severe hemorrhagic side effects The first symptoms of acute ischemia to tPA treatment andquot time to needleandquot can span hours even in developed urban areas since ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Gene Based Therapy for Congestive Heart Failure P2 SBIR

    SBC: Nanocor Therapeutics, Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Congestive heart failure is a major cause of morbidity and mortality in the United States. While progress in conventional treatments is making steady and incremental gains to reduce heart failure mortality, there is a critical need to explore new therapeutic approaches. It is now apparent that gene therapy has broader potential in diseases such as congestive he ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. IDENTIFICATION OF NEW ACETYL-COA CARBOXYLASE INHIBITORS

    SBC: CROPSOLUTION, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Acetyl-CoA carboxylase (ACC) catalyzes the first step in fatty acid biosynthesis and its product, malonyl-CoA, inhibits fatty acid oxidation. These functions make ACC a prime target for the development of therapeutics to treat obesity and type 2 diabetes. Knockout studies in mice, and animal studies with ACC inhibitors, have validated this approach. The most po ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
  10. Insulating Coatings for Implant Devices and Ribbon Cables

    SBC: PREMITEC, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Summary Advancements in device miniaturization, integrated circuits packaging, microfabrication technologies, and biocompatible materials have made possible the development of complex neural prostheses designed to restore lost functions such as movement, hearing or vision. Neurological diseases result in significant impairment for millions of individuals worldw ...

    SBIR Phase II 2006 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government